戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ields up to 84% starting from isomannide and isosorbide.
2  atenolol 100 mg was added to amlodipine and isosorbide 5-mononitrate 100 mg to diltiazem (Adizem XL)
3 mlodipine/atenolol and diltiazem (Adizem XL)/isosorbide 5-mononitrate on exercise and ambulatory myoc
4 e/atenolol superior to diltiazem (Adizem XL)/isosorbide 5-mononitrate.
5 eduction of portal pressure (propranolol and isosorbide-5-mononitrate; n = 95).
6  hydroformylation on olefinic derivatives of isosorbide and isomannide is shown by which a new carbon
7                                  Nifedipine, isosorbide, and nitroglycerin were further evaluated for
8 erences were observed between isomannide and isosorbide-based elastomers where the latter displays su
9 s of oxalate ester bonds (especially oxalate isosorbide bonds), which mostly hydrolyzed completely wi
10  fully renewable (bio- and CO(2)-based) poly(isosorbide-co-diol) oxalate (PISOX-diol) copolyesters wa
11 opening polymerization (ROP) of an annulated isosorbide derivative (1,4:2,5:3,6-trianhydro-d-mannitol
12                  In this study, we evaluated isosorbide di-(linoleate/oleate) (IDL), which was genera
13           Finally, an intracoronary bolus of isosorbide dinitrate (1000 microgram) was given.
14  not SV dilated in response to adenosine and isosorbide dinitrate (all P<0.05, RA versus SV, percent
15              In clinical trials, hydralazine-isosorbide dinitrate (H-ISDN) for heart failure with red
16 ceived either 100 mg of sildenafil, 10 mg of isosorbide dinitrate (ISDN) or placebo during exercise o
17 creased overall mortality versus hydralazine/isosorbide dinitrate (p < 0.035) in V-HeFT II.
18                   Ivabradine and hydralazine/isosorbide dinitrate also have a role in the care of cer
19  of treatment with fixed-dose combination of isosorbide dinitrate and hydralazine (FDC I/H) in patien
20                    Fixed-dose combination of isosorbide dinitrate and hydralazine (FDC-I/H) reduced m
21 ing enzyme inhibitors and the combination of isosorbide dinitrate and hydralazine differs in black an
22  reported that the fixed-dose combination of isosorbide dinitrate and hydralazine hydrochloride (FDC
23  with greater impact of fixed combination of isosorbide dinitrate and hydralazine on the primary comp
24     We examined whether a fixed dose of both isosorbide dinitrate and hydralazine provides additional
25 ricle remodeling, outcomes and the impact of isosorbide dinitrate and hydralazine.
26                                              Isosorbide dinitrate and nitroglycerin markedly inhibite
27 Although the combined use of hydralazine and isosorbide dinitrate confers important clinical benefits
28  and a fixed dose combination of hydralazine-isosorbide dinitrate in 2005.
29 ts in 24.1% (87.4% of eligible), hydralazine/isosorbide dinitrate in 8.6% (93.1% of eligible), and an
30 sion was also observed in vivo in rats given isosorbide dinitrate in the drinking water, with a dose-
31  overall effect of hydralazine hydrochloride-isosorbide dinitrate in the mostly white patient populat
32 in the placebo group than in the group given isosorbide dinitrate plus hydralazine (10.2 percent vs.
33 randomly assigned to receive a fixed dose of isosorbide dinitrate plus hydralazine or placebo in addi
34  was significantly better in the group given isosorbide dinitrate plus hydralazine than in the placeb
35              The addition of a fixed dose of isosorbide dinitrate plus hydralazine to standard therap
36 r in combination with nitroglycerin (NTG) or isosorbide dinitrate restores Ca(2+) cycling and contrac
37 combination of hydralazine hydrochloride and isosorbide dinitrate was approved by the U.S. Food and D
38 placebo therapy in V-HeFT I, and hydralazine/isosorbide dinitrate was compared with enalapril in V-He
39 on fraction >35%, treatment with hydralazine/isosorbide dinitrate was compared with prazosin and plac
40 w responses to adenosine, acetylcholine, and isosorbide dinitrate were comparable.
41 ions that compared hydralazine hydrochloride-isosorbide dinitrate with placebo or with enalapril.
42 t failure who took hydralazine hydrochloride-isosorbide dinitrate with standard therapy experienced a
43 03 for acetylcholine and r=-0.62, P=0.05 for isosorbide dinitrate) but not in LITA (r=-0.18, P=0.63 f
44 63 for acetylcholine and r=-0.11, P=0.75 for isosorbide dinitrate).
45 n of hydralazine hydrochloride, 37.5 mg, and isosorbide dinitrate, 20 mg, for treating heart failure
46 ockers, aldosterone antagonists, hydralazine/isosorbide dinitrate, and anticoagulants.
47 ethylenetriamine-NO and the organic nitrate, isosorbide dinitrate, the inhibitory effects of NO-aspir
48  succinate, bisoprolol, carvedilol, digoxin, isosorbide dinitrate-hydralazine, spironolactone, and ep
49 d by selective infusion of acetylcholine and isosorbide dinitrate.
50 t infusions of adenosine, acetylcholine, and isosorbide dinitrate.
51 y and sudden death compared with hydralazine/isosorbide dinitrate.
52  heart failure when given concomitantly with isosorbide dinitrate.
53                      Previous trials testing isosorbide dinitrate/hydralazine (I/H) were performed in
54                    Fixed-dose combination of isosorbide dinitrate/hydralazine (ISDN/HYD) improved cli
55                   Oxalic acid from CO(2) and isosorbide from biomass are interesting rigid building b
56                                              Isosorbide is a rigid, sugar-derived building block that
57 azones connected nonsymmetrically through an isosorbide linker, which exhibit highly efficient, ortho
58 s composed of bistable hydrazones and chiral isosorbide moieties.
59 whereas, more women developed headache after isosorbide mononitrate (27%) than after gemeprost (0%).
60 ly and significantly with increased doses of isosorbide mononitrate (but not placebo).
61 igned to a 6-week dose-escalation regimen of isosorbide mononitrate (from 30 mg to 60 mg to 120 mg on
62 men taking the nitric oxide (NO) donor drugs isosorbide mononitrate (ISMN) or glyceryl trinitrate (GT
63 agonist amlodipine (10 mg once daily) versus isosorbide mononitrate (ISMN, 50 mg once daily) on poste
64 gned to receive before surgery, per vaginam, isosorbide mononitrate 40 mg or 80 mg, or the prostaglan
65 nal administration of the nitric oxide donor isosorbide mononitrate can induce effective ripening of
66                                              Isosorbide mononitrate could be used as an alternative t
67  oxide donors such as glyceryl trinitrate or isosorbide mononitrate could be used to deliver nitric o
68 ntraoperative blood loss with either dose of isosorbide mononitrate did not differ from those in a co
69    During all dose regimens, activity in the isosorbide mononitrate group was lower than that in the
70 essed during a 14-day period before starting isosorbide mononitrate or placebo (n=110).
71                    We compared the effect of isosorbide mononitrate or placebo on daily activity in s
72                                              Isosorbide mononitrate reduced recurrent stroke in 353 p
73       More women remained symptom-free after isosorbide mononitrate than after gemeprost (28/44 [64%]
74                            Pretreatment with isosorbide mononitrate to ripen the cervix before first-
75 d a preserved ejection fraction who received isosorbide mononitrate were less active and did not have
76    In the group receiving the 120-mg dose of isosorbide mononitrate, as compared with the placebo gro
77 compared with 3% and 0%, respectively, after isosorbide mononitrate, whereas, more women developed he
78  6-minute walk distance, and NT-proBNP) with isosorbide mononitrate.
79           Nonselective beta-blockers (NSBB), isosorbide-mononitrate (ISMN), carvedilol, and variceal
80 act was also suppressed by administration of isosorbide or theophylline in the drinking water.
81 on, whether at the 2' or 5' positions of the isosorbide unit, or the attachment of the chiral unit to
82 form for tailored polymer architectures from isosorbide via ROP.
83 e) (IDL), which was generated by esterifying isosorbide with sunflower fatty acids.